Fulcrum Therapeutics, Inc. financial data

Symbol
FULC on Nasdaq
Industry
Pharmaceutical Preparations
Location
26 Landsdowne Street, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.95K % +11.1%
Debt-to-equity 8.54 % -13.2%
Return On Equity -7.31 % +81%
Return On Assets -6.74 % +80.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 53.9M shares -12.8%
Common Stock, Shares, Outstanding 53.9M shares +3.53%
Common Stock, Value, Issued 54K USD -12.9%
Weighted Average Number of Shares Outstanding, Basic 62K shares +3.79%
Weighted Average Number of Shares Outstanding, Diluted 62K shares +3.79%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 70.7M USD -0.98%
General and Administrative Expense 38.6M USD -7.96%
Operating Income (Loss) -30.5M USD +72.5%
Net Income (Loss) Attributable to Parent -17.9M USD +81.9%
Earnings Per Share, Basic -0.3 USD/shares +81.7%
Earnings Per Share, Diluted -0.32 USD/shares +80.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 72.6M USD +141%
Assets, Current 267M USD +1.9%
Property, Plant and Equipment, Net 4.22M USD -25.3%
Operating Lease, Right-of-Use Asset 6.02M USD -21.4%
Other Assets, Noncurrent 76K USD -96.2%
Assets 279M USD +0.05%
Accounts Payable, Current 4.04M USD +13.1%
Employee-related Liabilities, Current 3.82M USD -5.07%
Liabilities, Current 14.5M USD +3.08%
Operating Lease, Liability, Noncurrent 7.01M USD -23.3%
Other Liabilities, Noncurrent 197K USD 0%
Liabilities 21.7M USD -7.26%
Accumulated Other Comprehensive Income (Loss), Net of Tax 379K USD
Retained Earnings (Accumulated Deficit) -503M USD -3.69%
Stockholders' Equity Attributable to Parent 257M USD +0.72%
Liabilities and Equity 279M USD +0.05%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25.3M USD -4.84%
Net Cash Provided by (Used in) Financing Activities 1.65M USD -98.6%
Net Cash Provided by (Used in) Investing Activities 38.1M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 53.9M shares -12.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 14.5M USD
Deferred Tax Assets, Valuation Allowance 130M USD -21.3%
Deferred Tax Assets, Gross 133M USD -20.5%
Depreciation 1.79M USD -20.5%
Payments to Acquire Property, Plant, and Equipment 28K USD -83.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -16.6M USD +83.1%
Property, Plant and Equipment, Gross 18.1M USD +0.74%
Operating Lease, Liability, Current 2.13M USD -9.19%
Deferred Tax Assets, Operating Loss Carryforwards 75M USD -12.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 3.19M USD +29.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%